Stockscreener 앱 받기
10.49
2.86%
0.3401
Trevi Therapeutics Inc 주식(TRVI)의 최신 뉴스
Will Trevi Therapeutics Inc outperform its industry peersDip Buying & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Weekly Recap: Does Trevi Therapeutics Inc offer margin of safetyShort Setup & Verified High Yield Trade Plans - baoquankhu1.vn
Coulter Partners Recruits CFO for Trevi Therapeutics - Hunt Scanlon Media
Is Trevi Therapeutics Inc a momentum stockEarnings Performance Report & Detailed Earnings Play Strategies - baoquankhu1.vn
Trevi Therapeutics Advances Toward Key Regulatory Review Following Clinical Validation - AD HOC NEWS
Trevi Therapeutics (NASDAQ:TRVI) Shares Down 6.5%Here's Why - MarketBeat
Trevi Therapeutics (TRVI) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Trevi Therapeutics (TRVI) Publishes Positive Phase 2b Trial Resu - GuruFocus
Experimental cough pill lets most IPF patients cut daily coughing in half - Stock Titan
Aug Action: Is Trevi Therapeutics Inc a top pick in the sectorJuly 2025 PreEarnings & Low Risk High Win Rate Picks - baoquankhu1.vn
Is Trevi Therapeutics Inc. stock technically oversoldBear Alert & Accurate Buy Signal Alerts - bollywoodhelpline.com
New trial links cough counts to how IPF patients feel on oral treatment - Stock Titan
Will Trevi Therapeutics Inc outperform tech stocksPortfolio Gains Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
Trevi Therapeutics’ Earnings Call Highlights Promising Outlook - MSN
Coulter Partners successfully led a search assignment for Trevi Therapeutics, Inc. (Nasdaq: TRVI) and is pleased to announce the placement of David Hastings as Chief Financial Officer (CFO) - Hunt Scanlon Media
Trevi Therapeutics (TRVI) targets next phase of growth with leadership change - MSN
Aug Technicals: Can Trevi Therapeutics Inc continue delivering strong returns - baoquankhu1.vn
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Recommendation of “Buy” by Brokerages - Defense World
Trevi Therapeutics (TRVI) Valuation Check After FDA End Of Phase 2 Update And Renewed Analyst Optimism - Yahoo Finance
Is Trevi Therapeutics (TRVI) Building a Multi-Indication Moat With Its Nalbuphine ER Cough Strategy? - Yahoo Finance
Peregrine Capital Management LLC Invests $5.68 Million in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Given “Buy” Rating at HC Wainwright - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Earns Buy Rating from HC Wainwright - MarketBeat
Trevi Therapeutics (TRVI) Receives Reiterated 'Buy' Rating from HC Wainwright & Co. | TRVI Stock News - GuruFocus
Trevi Therapeutics’ (TRVI) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference - Sahm
Published on: 2026-01-09 09:26:05 - Улправда
Will Trevi Therapeutics Inc. stock maintain momentum in 2025Quarterly Growth Report & Long Hold Capital Preservation Plans - Улправда
Will Trevi Therapeutics Inc. stock split again soonJuly 2025 Macro Moves & Community Consensus Trade Alerts - Улправда
Growth Value: Can Trevi Therapeutics Inc. stock maintain growth trajectoryProfit Target & Verified Entry Point Signals - ulpravda.ru
Can Trevi Therapeutics Inc. stock maintain growth trajectoryJuly 2025 Intraday Action & Reliable Breakout Stock Forecasts - Улправда
Sentiment Recap: Can TPIC stock surprise with earnings upsideJuly 2025 Earnings & Comprehensive Market Scan Insights - moha.gov.vn
Aug Shorts: Can Trevi Therapeutics Inc stock maintain growth trajectory2025 Winners & Losers & Reliable Momentum Entry Alerts - Bộ Nội Vụ
What dividend safety score for Trevi Therapeutics Inc. stockPortfolio Profit Report & Weekly High Potential Alerts - Улправда
Trevi Therapeutics Outlines Key Development Milestones for Lead Drug Candidate - AD HOC NEWS
Is Trevi Therapeutics Inc. stock trading at a premium valuation2025 Sector Review & Capital Efficiency Focused Strategies - Улправда
Trevi Therapeutics schedules FDA meeting for chronic cough program By Investing.com - Investing.com India
Will Trevi Therapeutics Inc. stock gain from strong economy2025 Institutional Moves & Technical Buy Zone Confirmation - Улправда
Will Trevi Therapeutics Inc. stock rally after Fed decisionsJuly 2025 Opening Moves & Stock Portfolio Risk Management - Улправда
Why Trevi Therapeutics Inc. stock remains on buy listsJuly 2025 EndofMonth & Weekly Watchlist for Consistent Profits - Улправда
Published on: 2026-01-08 19:22:53 - ulpravda.ru
Why Trevi Therapeutics Inc. stock could outperform in 2025Quarterly Profit Review & AI Powered Buy/Sell Recommendations - Улправда
Trevi Therapeutics (TRVI) Analyst Rating Update: Buy Rating Main - GuruFocus
Trevi Therapeutics' (TRVI) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
Trevi Therapeutics schedules FDA meeting for chronic cough program - Investing.com
TRVI Stock Falls -15% With A 7-day Losing Spree On Technical Breakdown - Trefis
Published on: 2026-01-03 15:10:39 - moha.gov.vn
Trevi Therapeutics (NASDAQ:TRVI) Stock Price Down 6.3%Here's Why - MarketBeat
Quarterly Recap: What dividend safety score for Trevi Therapeutics Inc stockStock Surge & AI Optimized Trading Strategy Guides - moha.gov.vn
Published on: 2025-12-31 06:38:59 - moha.gov.vn
Oppenheimer Boosts Trevi Therapeutics (TRVI) PT to $23, Cites Positive Haduvio Trial Results - MSN
Trevi Therapeutics (TRVI) Targets Next Phase of Growth with Leadership Change - Finviz
Flputnam Investment Management Co. Raises Stock Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
2.35%
0.51%
자본화:
|
볼륨(24시간):